Just before the open of US equity market trade, the US Food and Drug Administration announced that it had approved a second Covid-19 treatment pill for at-home use. Early trials suggest that Merck’s molnupiravir could reduce mortality and hospitalisation rates in at-home patients by as much as 50%. The news comes after the FDA announced on Wednesday that they had approved Pfizer’s paxlovid pill, which early trails showed to have a superior up to 90% efficacy in preventing hospitalisation and death in at-risk patients.
Just as the news of the Pfizer approval helped stoke risk appetite on Wednesday, the announcement prior to the equity open was likely contributed to the S&P 500’s post-open surge. The index, which had moved a tad higher in pre-market trade (according to index futures) and managed to reclaim the 4700 level, opened at 4706 but has since surged into the 4720s. That means the index is up 0.6% on Wednesday’s close in the 4690s and trades just 0.4% below intraday highs printed back on 22 November in the 4740s.
The Nasdaq 100 index is up about 0.5% and the Dow is up about 0.6%, showing that the gains in equity markets are broad-based. The S&P 500 CBOE volatility index (or VIX) fell another half a point and trades at monthly lows close to 18.00. Alongside the news of the recent approval of two at-home Covid-19 treatment pills, risk appetite in US equities has been boosted in recent days by the release of three separate studies (from South Africa, Scotland and London) which all showed Omicron to be significantly milder than Delta.
The news has eased pressure on European authorities to lockdown their economies in order to curb transmission. The S&P 500 index is now more than 4.0% up versus Monday’s lows in the 4530s. If the S&P 500 closes at current levels, that would mark a record closing high just in time for Christmas – bear in mind that US equity markets are shut on Friday. After a bumpy, volatile December, where the S&P 500 index was at one point as much as 5.0% below recent record highs, the “Santa Rally” has finally arrived to save the day.
© 2000-2024. All rights reserved.
This site is managed by Teletrade D.J. LLC 2351 LLC 2022 (Euro House, Richmond Hill Road, Kingstown, VC0100, St. Vincent and the Grenadines).
The information on this website is for informational purposes only and does not constitute any investment advice.
The company does not serve or provide services to customers who are residents of the US, Canada, Iran, The Democratic People's Republic of Korea, Yemen and FATF blacklisted countries.
Making transactions on financial markets with marginal financial instruments opens up wide possibilities and allows investors who are willing to take risks to earn high profits, carrying a potentially high risk of losses at the same time. Therefore you should responsibly approach the issue of choosing the appropriate investment strategy, taking the available resources into account, before starting trading.
Use of the information: full or partial use of materials from this website must always be referenced to TeleTrade as the source of information. Use of the materials on the Internet must be accompanied by a hyperlink to teletrade.org. Automatic import of materials and information from this website is prohibited.
Please contact our PR department if you have any questions or need assistance at pr@teletrade.global.